1 / 2

FDA Accelerates Approval of GSK PD-1 Antibody To Treat dMMR Solid Tumors

On August 17, GlaxoSmithKline plc (GSK) announced that the U.S. Food and Drug Administration (FDA) has accelerated the approval of its PD-1 antibody Jemperli (dostarlimab-gxly) for extended indications for the treatment of patients with relapsed or advanced solid tumors with mismatch repair-deficient (dMMR).

sunnyfang1419
Download Presentation

FDA Accelerates Approval of GSK PD-1 Antibody To Treat dMMR Solid Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Huateng Pharma https://en.huatengsci.com FDA Accelerates Approval of GSK PD-1 Antibody To Treat dMMR Solid Tumors On August 17, GlaxoSmithKline plc (GSK) announced that the U.S. Food and Drug Administration (FDA) has accelerated the approval of its PD-1 antibody Jemperli (dostarlimab-gxly) for extended indications for the treatment of patients with relapsed or advanced solid tumors with mismatch repair-deficient (dMMR). The dMMR characteristics of these patients were confirmed by FDA-approved tests, the disease continued to progress after receiving the prior treatment, and there were no other satisfactory alternative treatment options. This is Jemperli's second indication approved by the FDA this year. Mismatch repair-deficient tumor cells affect the normal repair of DNA damage during DNA replication. It is a biomarker that predicts the response to immune checkpoint inhibitors. Tumors carrying this biomarker mostly occur in endometrial cancer, colorectal cancer and gastrointestinal cancer, but may also occur in other solid tumors. This approval is based on the results of a clinical trial called GARNET. The results showed that among all patients with dMMR solid tumors, Jemperli's objective response rate was 41.6% (95% CI; 34.9-48.6), and the complete response rate

  2. Huateng Pharma was 9.1%. The median duration of response was 34.7 months, and 95.4% of patients had a response lasting more than 6 months. https://en.huatengsci.com Among the 267 patients with relapsed or advanced dMMR solid tumors that can be assessed for safety, the most commonly reported adverse reactions (≥20%) are fatigue/weakness (42%), anemia (30%), diarrhea (25%) and nausea (22%). The most common grade 3 or 4 adverse reactions (≥2%) are anemia, fatigue/weakness, elevated transaminases, sepsis, and acute kidney injury. Grade 3 or 4 laboratory value abnormalities (≥2%) include lymphopenia, reduced sodium, increased alkaline phosphatase, and decreased albumin levels. Dr. Hal Barron, Chief Scientific Officer and President of Research and Development of GSK, said: “Patients whose tumors carry dMMR biomarkers continue to require new and effective treatments. I am excited about GSK’s second FDA oncology approval this year, which provides patients with a New treatment options.” As a professional pharmaceutical intermediates supplier, Huateng Pharma is committed to supplying the services of anti-cancer intermediates's process development and scale-up production with capacities varying from gram to kilograms and multi tons. We have our own industrial park of 34,000 square meters that has been completed and put into operation since 2020 to support multi tons production. Reference: GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours.

More Related